Beta-secretase-1 antisense RNA is associated with vascular ageing and atherosclerotic cardiovascular disease

• Verfasst von: Bampatsias, Dimitrios [VerfasserIn]
• Verfasst von: Mavroeidis, Ioannis [VerfasserIn]
• Verfasst von: Tual-Chalot, Simon [VerfasserIn]
• Verfasst von: Vlachogiannis, Nikolaos I. [VerfasserIn]
• Verfasst von: Bonini, Francesca [VerfasserIn]
• Verfasst von: Sachse, Marco [VerfasserIn]
• Verfasst von: Mavraganis, Georgios [VerfasserIn]
• Verfasst von: Mareti, Alexia [VerfasserIn]
• Verfasst von: Kritsioti, Chrysoula [VerfasserIn]
• Verfasst von: Laina, Ageliki [VerfasserIn]
• Verfasst von: Delialis, Dimitrios [VerfasserIn]
• Verfasst von: Ciliberti, Giorgia [VerfasserIn]
• Verfasst von: Sopova, Kateryna [VerfasserIn]
• Verfasst von: Gatsiou, Aikaterini [VerfasserIn]
• Verfasst von: Martelli, Fabio [VerfasserIn]
• Verfasst von: Georgiopoulos, Georgios [VerfasserIn]
• Verfasst von: Stellos, Konstantinos [VerfasserIn]
• Verfasst von: Stamatelopoulos, Kimon [VerfasserIn]
• Titel: Beta-secretase-1 antisense RNA is associated with vascular ageing and atherosclerotic cardiovascular disease
• Titelzusatz: atherosclerosis and ischaemic disease
• Verf.angabe: Dimitrios Bampatsias, Ioannis Mavroeidis, Simon Tual-Chalot, Nikolaos I. Vlachogiannis, Francesca Bonini, Marco Sachse, Georgios Mavraganis, Alexia Mareti, Chrysoula Kritsioti, Ageliki Laina, Dimitrios Delialis, Giorgia Ciliberti, Kateryna Sopova, Aikaterini Gatsiou, Fabio Martelli, Georgios Georgiopoulos, Konstantinos Stellos, Kimon Stamatelopoulos
• E-Jahr: 2022
• Jahr: September 27, 2022
• Umfang: 11 S.
• Fussnoten: Gesehen am 04.07.2023
• Titel Quelle: Enthalten in: Thrombosis and haemostasis
• Ort Quelle: Stuttgart : Thieme, 1976
• Jahr Quelle: 2022
• Band/Heft Quelle: 122(2022), 11, Seite 1932-1942
• ISSN Quelle: 2567-689X
• DOI: doi:10.1055/a-1914-2094
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 185153489X

Abstract

Background: The noncoding antisense transcript for β-secretase-1 (BACE1-AS) is a long noncoding RNA with a pivotal role in the regulation of amyloid-β (Aβ). We aimed to explore the clinical value of BACE1-AS expression in atherosclerotic cardiovascular disease (ASCVD).Methods: Expression of BACE1-AS and its target, β-secretase 1 (BACE1) mRNA, was measured in peripheral blood mononuclear cells derived from 434 individuals (259 without established ASCVD [non-CVD], 90 with stable coronary artery disease [CAD], and 85 with acute coronary syndrome). Intima-media thickness and atheromatous plaques evaluated by ultrasonography, as well as arterial wave reflections and pulse wave velocity, were measured as markers of subclinical ASCVD. Patients were followed for a median of 52 months for major adverse cardiovascular events (MACE). Results: In the cross-sectional arm, BACE1-AS expression correlated with BACE1 expression (r = 0.396, p < 0.001) and marginally with Aβ1-40 levels in plasma (r = 0.141, p = 0.008). Higher ACE1-AS was associated with higher estimated CVD risk assessed by HeartScore for non-CVD subjects and by European Society of Cardiology clinical criteria for the total population (p < 0.05 for both). BACE1-AS was associated with higher prevalence of CAD (odds ratio [OR] = 1.85, 95% confidence interval [CI]: 1.37-2.5), multivessel CAD (OR = 1.36, 95% CI: 1.06-1.75), and with higher number of diseased vascular beds (OR = 1.31, 95% CI: 1.07-1.61, for multiple diseased vascular beds) after multivariable adjustment for traditional cardiovascular risk factors. In the prospective arm, BACE1-AS was an independent predictor of MACE in high cardiovascular risk patients (adjusted hazard ratio = 1.86 per ascending tertile, 95% CI: 1.011-3.43, p = 0.046). Conclusion: BACE1-AS is associated with the incidence and severity of ASCVD.